An FDA-approved antagonist of IL-1R for rheumatoid arthritis has been evaluated for the clinical management of cancer metastasis (Holen et al., 2016) (ClinicalTrials.gov identifier: NCT00072111) and a monoclonal antibody against IL-1α (Hong et al., 2014) is in phase III of clinical trials for colorectal cancer (ClinicalTrials.gov identifier: NCT01767857). This evidence concerns the gene IL1R1 and cancer.